Tarek Sabagh is an Oncology physician affiliated with Wright State University. OpenAlex indexes 5 publications with 486 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3120 Governors Place Blvd
Kettering, OH 454091328
Telephone
937-293-1622Provider last certified this registry record 30 Dec 2020.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20259 payments
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20247 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34%Aromatase Inhibitor21.2%Letrozole62%Anastrozole38%Part D<11 patientsAntimetabolite6.3%Hydroxyurea100%Part D<11 patients+ 2 more classes in this area
Blood & clotting
15.5%Factor Xa inhibitor13%Eliquis57%Xarelto44%Part D<11 patientsThrombopoietin Receptor Agonist2.5%Promacta100%Part D<11 patientsNervous system
15.1%Opioid Agonist5.7%Fentanyl56%Oxycodone-Acetaminophen44%Part D<11 patientsGabapentinoids4.8%Gabapentin100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Journal of Clinical Oncology
2018 - Thrombotic Thrombocytopenic Purpura: A Case Presenting with Acute Ischemic Colitis
Case Reports in Hematology
2013 - N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)
Journal of Clinical Oncology
2005
Similar KOLs
Other experts from the same institution or the same specialty.
John Fleishman, MD
Wright State University
Mohammad Saklayen, MD
Wright State University
Lionel Chow, MD, PhD
Wright State University
Jiri Sonek, MD
Wright State University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”